Larotrectinib
| Overview | |
| Catalog # | bs-83042c-5-mg |
| Product Name | Larotrectinib |
| Specifications | |
| Storage Buffer | White solid |
| Storage Condition | RT |
| Target | |
| Product Information | Larotrectinib is a potent (IC50’s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C).1 It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions.2-4 Larotrectinib is the first tissue agnostic drug approved by the FDA. |
| Description | CAS Number: 1223403-58-4 Chemical Name: (3S)-N-[5-[(2R)-2-(2,5-Difluorophenyl)pyrrolidine-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Molecular weight: 428.44 Formula: C21H22F2N6O2 Solubility: DMSO (5 mg/ml) Physical Properties: Yellow solid Purity: 98% by HPLC NMR (Conforms) |
Powered by Bioz